Efficacy of Three Aflibercept Injections for Neovascular Age-related Macular Degeneration Showing Limited Response to Ranibizumab. |
Kyung Min Kim, Jae Hui Kim, Young Suk Chang, Jong Woo Kim, Chul Gu Kim, Dong Won Lee |
1Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea. kjh7997@daum.net 2Department of Ophthalmology, Konyang University College of Medicine, Daejeon, Korea. |
라니비주맙 치료에 반응이 제한적인 습성황반변성에서 3회 애플리버셉트 주입술의 효과 |
김경민1⋅김재휘1⋅장영석2⋅김종우1⋅김철구1⋅이동원1 |
건양대학교 의과대학 김안과병원 안과학교실1, 건양대학교 의과대학 안과학교실2 |
|
Abstract |
PURPOSE To evaluate the efficacy of 3 bimonthly aflibercept injections for neovascular age-related macular degeneration (AMD) that showed limited response to 3 initial ranibizumab injections. METHODS: Three bimonthly aflibercept injections were performed for 21 eyes with neovascular AMD that was refractory to 3 monthly ranibizumab injections. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were measured at diagnosis, 1 month after 3 ranibizumab injections, and 1 month after 3 aflibercept injections, and these values were compared. RESULTS: The mean logarithm of minimal angle of resolution (logMAR) BCVA at diagnosis, after ranibizumab therapy, and after aflibercept therapy was 0.62 ± 0.29, 0.73 ± 0.31, and 0.65 ± 0.28, respectively. The CRT at the aforementioned times was 427.0 ± 98.7 µm, 409.5 ± 78.7 µm, and 315.9 ± 98.2 µm, respectively. When compared with the value measured after ranibizumab therapy, CRT was significantly decreased after aflibercept therapy (p < 0.001), whereas there was no significant difference in BCVA (p = 0.092) between the two times. Improved BCVA was noted in 8 eyes (38.1%) after aflibercept therapy and BCVA was unchanged in 11 eyes (52.4%). Decreased CRT was noted in 18 eyes (85.7%) after aflibercept therapy. CONCLUSIONS: Three bimonthly aflibercept injections were found to be useful in terms of improving or maintaining visual acuity, as well as reducing retinal thickness in neovascular AMD that showed limited response to 3 initial ranibizumab injections. |
Key Words:
Aflibercept;Age-related macular degeneration;Anti-vascular endothelial growth factor;Ranibizumab |
|